IDEAS home Printed from https://ideas.repec.org/e/pli76.html
   My authors  Follow this author

Frank Lichtenberg

Personal Details

First Name:Frank
Middle Name:
Last Name:Lichtenberg
Suffix:
RePEc Short-ID:pli76
[This author has chosen not to make the email address public]
http://www8.gsb.columbia.edu/cbs-directory/detail/frl1
Courtney C. Brown Professor of Business Columbia University 504 Uris Hall 3022 Broadway New York, NY 10027
(212) 854-4408
Terminal Degree:1982 Department of Economics; University of Pennsylvania (from RePEc Genealogy)

Affiliation

(30%) National Bureau of Economic Research (NBER)

Cambridge, Massachusetts (United States)
http://www.nber.org/
RePEc:edi:nberrus (more details at EDIRC)

(10%) CESifo

München, Germany
https://www.cesifo.org/
RePEc:edi:cesifde (more details at EDIRC)

(60%) Finance and Economics Department
Graduate School of Business
Columbia University

New York City, New York (United States)
http://www.gsb.columbia.edu/finance
RePEc:edi:feclbus (more details at EDIRC)

Research output

as
Jump to: Working papers Articles Chapters

Working papers

  1. Katharina E. Blankart & Frank R. Lichtenberg, 2022. "The Effects of Off-label Drug Use on Disability and Medical Expenditure," NBER Working Papers 30440, National Bureau of Economic Research, Inc.
  2. Frank R. Lichtenberg, 2019. "The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis," CESifo Working Paper Series 7559, CESifo.
  3. Frank R. Lichtenberg, 2019. "How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013," NBER Working Papers 25483, National Bureau of Economic Research, Inc.
  4. Frank R. Lichtenberg, 2018. "The Long-run Impact of New Medical Ideas on Cancer Survival and Mortality," NBER Working Papers 25328, National Bureau of Economic Research, Inc.
  5. Frank R. Lichtenberg, 2018. "The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," Working Papers id:12757, eSocialSciences.
  6. Frank R. Lichtenberg, 2017. "The Impact of Public and Private Research Support on Premature Cancer Mortality and Hospitalization in the U.S., 1999-2013," NBER Working Papers 23241, National Bureau of Economic Research, Inc.
  7. Gisela Hostenkamp & Frank R. Lichtenberg, 2015. "Listen to your Doctor, or else!: Medication Under-use and Overuse and Long-term Health Outcomes of Danish Diabetes Patients," NBER Working Papers 21780, National Bureau of Economic Research, Inc.
  8. Frank Lichtenberg, 2015. "Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010," CESifo Working Paper Series 5166, CESifo.
  9. Frank R. Lichtenberg, 2015. "The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011," NBER Working Papers 21239, National Bureau of Economic Research, Inc.
  10. Frank Lichtenberg & Gisela Hostenkamp, 2013. "The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence," CESifo Working Paper Series 4516, CESifo.
  11. Frank R. Lichtenberg, 2013. "The Impact of Biomedical Knowledge Accumulation on Mortality: A Bibliometric Analysis of Cancer Data," NBER Working Papers 19593, National Bureau of Economic Research, Inc.
  12. Frank R. Lichtenberg, 2012. "The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files," NBER Working Papers 18552, National Bureau of Economic Research, Inc.
  13. Frank R. Lichtenberg, 2012. "The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey," NBER Working Papers 17750, National Bureau of Economic Research, Inc.
  14. Frank Lichtenberg & Billie Pettersson, 2012. "The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data," CESifo Working Paper Series 3894, CESifo.
  15. Frank R. Lichtenberg, 2012. "Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009," NBER Working Papers 18235, National Bureau of Economic Research, Inc.
  16. Frank R. Lichtenberg, 2011. "The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007," NBER Working Papers 17414, National Bureau of Economic Research, Inc.
  17. Frank R. Lichtenberg & Johannes Schoder, 2010. "Impact of Specialization on Health Outcomes – Evidence from U.S. Cancer Data," SOI - Working Papers 1011, Socioeconomic Institute - University of Zurich.
  18. Frank R. Lichtenberg, 2010. "Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A reexamination using data from the U.S. and Australia," NBER Working Papers 16051, National Bureau of Economic Research, Inc.
  19. Frank R. Lichtenberg, 2010. "Has medical innovation reduced cancer mortality?," NBER Working Papers 15880, National Bureau of Economic Research, Inc.
  20. Frank Lichtenberg, 2010. "The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France," CESifo Working Paper Series 3095, CESifo.
  21. Frank R. Lichtenberg, 2009. "The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth," NBER Working Papers 15068, National Bureau of Economic Research, Inc.
  22. Frank Lichtenberg, 2009. "Response to Baker and Fugh-Berman's Critique of my Paper, "Why has Longevity Increased more in some States than in others?"," CESifo Working Paper Series 2712, CESifo.
  23. Sule Akkoyunlu & Frank R. Lichtenberg & Boriss Siliverstovs & Peter Zweifel, 2009. "Spurious correlation in estimation of the health production function: A note," SOI - Working Papers 0903, Socioeconomic Institute - University of Zurich.
  24. Frank R. Lichtenberg, 2008. "Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003," NBER Working Papers 14008, National Bureau of Economic Research, Inc.
  25. Frank R. Lichtenberg & Gautier Duflos, 2008. "Pharmaceutical innovation and the longevity of Australians: a first look," NBER Working Papers 14009, National Bureau of Economic Research, Inc.
  26. Frank R. Lichtenberg, 2006. "Importation and Innovation," NBER Working Papers 12539, National Bureau of Economic Research, Inc.
  27. Frank R. Lichtenberg, 2006. "The Impact of New Laboratory Procedures and Other Medical Innovations on the Health of Americans, 1990-2003: Evidence from Longitudinal, Disease-Level Data," NBER Working Papers 12120, National Bureau of Economic Research, Inc.
  28. Frank R. Lichtenberg, 2006. "The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditures: An Assessment Based on Aggregate U.S. Time-Series Data," NBER Working Papers 12406, National Bureau of Economic Research, Inc.
  29. Frank R. Lichtenberg, 2004. "The Expanding Pharmaceutical Arsenal in the War on Cancer," NBER Working Papers 10328, National Bureau of Economic Research, Inc.
  30. Frank R. Lichtenberg, 2004. "The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program," NBER Working Papers 10884, National Bureau of Economic Research, Inc.
  31. Frank R. Lichtenberg & Joel Waldfogel, 2003. "Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act," NBER Working Papers 9750, National Bureau of Economic Research, Inc.
  32. Frank R. Lichtenberg, 2003. "The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001," NBER Working Papers 9754, National Bureau of Economic Research, Inc.
  33. Frank Lichtenberg, 2002. "Benefits and Costs of Newer Drugs: An Update," NBER Working Papers 8996, National Bureau of Economic Research, Inc.
  34. Frank R. Lichtenberg & Suchin Virabhak, 2002. "Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health"," NBER Working Papers 9351, National Bureau of Economic Research, Inc.
  35. Adriana Lleras-Muney & Frank R. Lichtenberg, 2002. "The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs," NBER Working Papers 9185, National Bureau of Economic Research, Inc.
  36. Frank Lichtenberg & Suchin Virabhak, 2002. "Using Patents Data to Map Technical Change in Health-Related Areas," OECD Science, Technology and Industry Working Papers 2002/16, OECD Publishing.
  37. Frank R. Lichtenberg, 2002. "The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output," NBER Working Papers 9139, National Bureau of Economic Research, Inc.
  38. Frank R. Lichtenberg & Tomas J. Philipson, 2002. "The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US," Working Papers 0209, Harris School of Public Policy Studies, University of Chicago.
  39. Frank R. Lichtenberg & Tomas J. Philipson, 2002. "The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry," NBER Working Papers 9303, National Bureau of Economic Research, Inc.
  40. Frank R. Lichtenberg, 2001. "The Effect of New Drugs on Mortality from Rare Diseases and HIV," NBER Working Papers 8677, National Bureau of Economic Research, Inc.
  41. Bruno Van Pottelsberghe & Frank Lichtenberg, 2001. "Does foreign direct investment transfer technology across borders?," ULB Institutional Repository 2013/6221, ULB -- Universite Libre de Bruxelles.
  42. Frank Lichtenberg, 2000. "The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey," CESifo Working Paper Series 404, CESifo.
  43. Deborah A. Freund & Frank R. Lichtenberg, 2000. "The Impact of Hospital Quality-Related Practices on Health Outcomes," Center for Policy Research Working Papers 18, Center for Policy Research, Maxwell School, Syracuse University.
  44. Frank Lichtenberg, 2000. "Sources of U.S. Longevity Increase, 1960 -1997," CESifo Working Paper Series 405, CESifo.
  45. Frank R. Lichtenberg, 1998. "Pharmaceutical Innovation, Mortality Reduction, and Economic Growth," NBER Working Papers 6569, National Bureau of Economic Research, Inc.
  46. Bruno Van Pottelsberghe & Frank Lichtenberg, 1998. "International R&D spillovers comment," ULB Institutional Repository 2013/6233, ULB -- Universite Libre de Bruxelles.
  47. Maryann P. Feldman & Frank R. Lichtenberg, 1997. "The Impact and Organization of Publicly-Funded Research and Development in the European Community," NBER Working Papers 6040, National Bureau of Economic Research, Inc.
  48. Frank Lichtenberg, 1997. "The Allocation of Publicly-Funded Biomedical Research," CESifo Working Paper Series 140, CESifo.
  49. Frank Lichtenberg & Bruno van Pottelsberghe de la Potterie, 1996. "International R&D Spillovers: A Re-Examination," NBER Working Papers 5668, National Bureau of Economic Research, Inc.
  50. Lichtenberg, F.R., 1996. "The European Strategic Program for Research in Information Technologie (ESPRIT): An Ex-Post Analysis," Papers 96-09, Columbia - Graduate School of Business.
  51. Lichtenberg, F.R. & Lehr, B., 1996. "Computer Use and Productivity Growth in federal Government Agencies," Papers 96-10, Columbia - Graduate School of Business.
  52. Lichtenberg, F.R., 1996. "The Effect of New Political Administration on Federal Government Productivity and Employment," Papers 96-11, Columbia - Graduate School of Business.
  53. William Lehr & Frank R. Lichtenberg, 1996. "Computer Use and Productivity Growth in Federal Government Agencies, 1987 to 1992," NBER Working Papers 5616, National Bureau of Economic Research, Inc.
  54. Frank R. Lichtenberg, 1996. "The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality," NBER Working Papers 5418, National Bureau of Economic Research, Inc.
  55. Frank R. Lichtenberg, 1993. "The Output Contributions of Computer Equipment and Personnel: A Firm- Level Analysis," NBER Working Papers 4540, National Bureau of Economic Research, Inc.
  56. Frank R. Lichtenberg & George M. Pushner, 1992. "Ownership Structure and Corporate Performance in Japan," NBER Working Papers 4092, National Bureau of Economic Research, Inc.
  57. Frank R. Lichtenberg, 1992. "R&D Investment and International Productivity Differences," NBER Working Papers 4161, National Bureau of Economic Research, Inc.
  58. Frank R. Lichtenberg, 1991. "Labor Market Institutions, Liquidity Constraints, and Macroeconomic Stability," NBER Working Papers 3926, National Bureau of Economic Research, Inc.
  59. Frank R. Lichtenberg, 1990. "Industrial De-Diversification and Its Consequences for Productivity," Economics Working Paper Archive wp_35, Levy Economics Institute.
  60. Donald Siegel & Frank R Lichtenberg, 1989. "Using Linked Census R&D-Lrd Data To Analyze The Effect Of R&D Investment On Total Factor Productivity Growth," Working Papers 89-2, Center for Economic Studies, U.S. Census Bureau.
  61. Frank R Lichtenberg & Donald Siegel, 1989. "The Effects Of Leveraged Buyouts On Productivity And Related Aspects Of Firm Behavior," Working Papers 89-5, Center for Economic Studies, U.S. Census Bureau.
  62. Frank R Lichtenberg & Donald Siegel, 1989. "The Effect Of Takeovers On The Employment And Wages Of Central-Office And Other Personnel," Working Papers 89-3, Center for Economic Studies, U.S. Census Bureau.
  63. Frank R. Lichtenberg & Moshe Kim, 1989. "The Effects of Mergers on Prices, Costs, And Capacity Utilization in the U.S. Air Transportation Industry, 1970-84," Economics Working Paper Archive wp_32, Levy Economics Institute.
  64. Frank R. Lichtenberg & Donald Siegel, 1989. "The Impact of R&D Investment On Productivity - New Evidence Using Linked R&D-LRD Data," NBER Working Papers 2901, National Bureau of Economic Research, Inc.
  65. Lichtenberg, F.R., 1988. "How Elastic Is The Government'S Demand For Weapons?," Papers fb-_88-39, Columbia - Graduate School of Business.
  66. Lichtenberg, F.R., 1988. "Contributions To Federal Election Campaigns By Government Contractors," Papers fb-_89-06, Columbia - Graduate School of Business.
  67. Lichtenberg, F.R., 1988. "Crowding Out: The Impact Of The Strategic Defense Initiative On U.S. Civilian R&D Investment And Industrial Competitiveness," Papers fb-_88-19, Columbia - Graduate School of Business.
  68. Frank R. Lichtenberg, 1988. "IR&D Project Data and Theories of R&D Investment," NBER Working Papers 2720, National Bureau of Economic Research, Inc.
  69. Lichtenberg, F.R., 1988. "Government Subsidies To Private Military R&D Investmen: Dod'S Ir&D Policy," Papers fb-_88-01, Columbia - Graduate School of Business.
  70. Ann P. Bartel & Frank R. Lichtenberg, 1988. "Technical Change, Learning, and Wages," NBER Working Papers 2732, National Bureau of Economic Research, Inc.
  71. Frank R. Lichtenberg & Zvi Griliches, 1986. "Errors of Measurement in Output Deflators," NBER Working Papers 2000, National Bureau of Economic Research, Inc.
  72. Frank R. Lichtenberg, 1986. "Private Investment in R&D to Signal Ability to Perform Government Contracts," NBER Working Papers 1974, National Bureau of Economic Research, Inc.
  73. Ann P. Bartel & Frank R. Lichtenberg, 1985. "The Comparative Advantage of Educated Workers in Implementing New Technology: Some Empirical Evidence," NBER Working Papers 1718, National Bureau of Economic Research, Inc.
  74. Zvi Griliches & Frank R. Lichtenberg, 1982. "R and D and Productivity at the Industry Level: Is There Still a Relationship?," NBER Working Papers 0850, National Bureau of Economic Research, Inc.
  75. Frank R. Lichtenberg, 1981. "Training, Tenure, and Productivity," NBER Working Papers 0671, National Bureau of Economic Research, Inc.

Articles

  1. Frank R. Lichtenberg, 2024. "Has pharmaceutical innovation reduced the average cost of U.S. health care episodes?," International Journal of Health Economics and Management, Springer, vol. 24(1), pages 1-31, March.
  2. Frank R. Lichtenberg, 2024. "The impact of biomedical innovation on the disability of elderly Medicare recipients, 2013–2019," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 33(2), pages 344-361, February.
  3. Frank R. Lichtenberg, 2022. "The effects of dynamic and static competition on prescription drug prices in Denmark, 1997–2017," Journal of Evolutionary Economics, Springer, vol. 32(4), pages 1155-1173, September.
  4. Frank R. Lichtenberg, 2022. "The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996–2019," Swiss Journal of Economics and Statistics, Springer;Swiss Society of Economics and Statistics, vol. 158(1), pages 1-24, December.
  5. Lichtenberg, Frank R., 2022. "The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries," Economics & Human Biology, Elsevier, vol. 46(C).
  6. Frank R. Lichtenberg, 2021. "Are drug prices subject to creative destruction? Evidence from the US, 1997–2017," Health Economics, John Wiley & Sons, Ltd., vol. 30(8), pages 1910-1932, August.
  7. Lichtenberg Frank R., 2021. "The Impact of Biopharmaceutical Innovation on Disability, Social Security Recipiency, and Use of Medical Care of U.S. Community Residents, 1998–2015," Forum for Health Economics & Policy, De Gruyter, vol. 24(1), pages 35-74, June.
  8. Lichtenberg, Frank, 2020. "The Health Impact of, and access to, New Drugs in Korea," East Asian Economic Review, Korea Institute for International Economic Policy, vol. 24(2), pages 127-164, June.
  9. Katharina E. Blankart & Frank R. Lichtenberg, 2020. "Are patients more adherent to newer drugs?," Health Care Management Science, Springer, vol. 23(4), pages 605-618, December.
  10. Frank R. Lichtenberg, 2019. "The long-run impact of new medical ideas on cancer survival and mortality," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 28(7), pages 722-740, October.
  11. Frank R. Lichtenberg, 2018. "The Impact of Public and Private Research on Premature Cancer Mortality and Hospitalization in the United States, 1999-2013," The American Economist, Sage Publications, vol. 63(2), pages 147-165, October.
  12. Lichtenberg Frank R., 2018. "The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis," Forum for Health Economics & Policy, De Gruyter, vol. 21(2), pages 1-20, December.
  13. Frank R. LICHTENBERG, 2018. "The Impact of New Drug Launch on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," JODE - Journal of Demographic Economics, Cambridge University Press, vol. 84(3), pages 309-354, September.
  14. Lichtenberg Frank R, 2018. "The Impact of New Drug Launches on Longevity Growth in Nine Middle Eastern and African Countries, 2007–2015," Review of Middle East Economics and Finance, De Gruyter, vol. 14(3), pages 1-15, December.
  15. Frank R. Lichtenberg, 2017. "The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia," The Economic Record, The Economic Society of Australia, vol. 93(302), pages 353-378, September.
  16. Lichtenberg Frank R., 2017. "The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004–2012," Forum for Health Economics & Policy, De Gruyter, vol. 20(1), pages 1-28, June.
  17. Frank R. Lichtenberg, 2017. "The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013," Latin American Economic Review, Springer;Centro de Investigaciòn y Docencia Económica (CIDE), vol. 26(1), pages 1-22, December.
  18. Frank R. Lichtenberg, 2015. "Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 277-299, July.
  19. Hostenkamp, Gisela & Lichtenberg, Frank R., 2015. "The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence," Social Science & Medicine, Elsevier, vol. 130(C), pages 162-171.
  20. Frank Lichtenberg, 2015. "The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011," International Journal of Health Economics and Management, Springer, vol. 15(3), pages 339-359, September.
  21. Frank Lichtenberg, 2015. "The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997–2010," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 207-222, April.
  22. Lichtenberg, Frank R. & Tatar, Mehtap & Çalışkan, Zafer, 2014. "The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010," Health Policy, Elsevier, vol. 117(3), pages 361-373.
  23. Frank R. Lichtenberg, 2014. "The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010," Journal of Human Capital, University of Chicago Press, vol. 8(4), pages 432-480.
  24. Frank R. Lichtenberg, 2014. "Has Medical Innovation Reduced Cancer Mortality?," CESifo Economic Studies, CESifo Group, vol. 60(1), pages 135-177.
  25. Lichtenberg, Frank R., 2014. "The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009," Economics & Human Biology, Elsevier, vol. 13(C), pages 107-127.
  26. Frank R. Lichtenberg & Billie Pettersson, 2014. "The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 23(3), pages 239-273, April.
  27. Lichtenberg Frank R., 2013. "The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996–2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files," Forum for Health Economics & Policy, De Gruyter, vol. 16(1), pages 1-33, January.
  28. Lichtenberg, Frank R., 2013. "The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000–2007," Social Science & Medicine, Elsevier, vol. 77(C), pages 50-59.
  29. Frank Lichtenberg, 2013. "The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 41-56, February.
  30. Frank Lichtenberg, 2012. "Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7," PharmacoEconomics, Springer, vol. 30(3), pages 197-211, March.
  31. Duflos, Gautier & Lichtenberg, Frank R., 2012. "Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization," International Review of Law and Economics, Elsevier, vol. 32(1), pages 95-109.
  32. Frank Lichtenberg, 2011. "The quality of medical care, behavioral risk factors, and longevity growth," International Journal of Health Economics and Management, Springer, vol. 11(1), pages 1-34, March.
  33. Frank Lichtenberg, 2011. "Has Pharmaceutical Innovation Reduced Social Security Disability Growth?," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 18(2), pages 293-316.
  34. Lichtenberg Frank R., 2010. "Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia," Forum for Health Economics & Policy, De Gruyter, vol. 13(2), pages 1-18, August.
  35. Sule Akkoyunlu & Frank R. Lichtenberg & Boriss Siliverstovs & Peter Zweifel, 2010. "Spurious correlation in estimation of the health production function: A note," Economics Bulletin, AccessEcon, vol. 30(3), pages 2505-2514.
  36. Lichtenberg, Frank, 2010. "Pharmaceutical innovation and mortality in the United States, 1960-2000. A commentary on Schnittker and Karandinos," Social Science & Medicine, Elsevier, vol. 70(7), pages 969-971, April.
  37. Lichtenberg Frank R., 2010. "Pharmaceutical Price Discrimination and Social Welfare," Capitalism and Society, De Gruyter, vol. 5(1), pages 1-32, July.
  38. Frank Lichtenberg, 2009. "The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 18(5), pages 407-428.
  39. Frank R. Lichtenberg, 2009. "Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country‐level data on 20 OECD countries, 1995–2003," Health Economics, John Wiley & Sons, Ltd., vol. 18(5), pages 519-534, May.
  40. Lichtenberg Frank R., 2008. "Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data," Forum for Health Economics & Policy, De Gruyter, vol. 10(1), pages 1-27, March.
  41. Frank R. Lichtenberg & Suchin Virabhak, 2007. "Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'Equipment for Your Health'," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 371-392.
  42. Frank R. Lichtenberg, 2007. "Benefits and costs of newer drugs: an update," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 485-490.
  43. Frank R. Lichtenberg, 2007. "Importation And Innovation," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 16(6), pages 403-417.
  44. Frank R. Lichtenberg, 2007. "The Impact of New Drugs on US Longevity and Medical Expenditure, 1990–2003: Evidence from Longitudinal, Disease-Level Data," American Economic Review, American Economic Association, vol. 97(2), pages 438-443, May.
  45. Frank Lichtenberg, 2006. "The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003," PharmacoEconomics, Springer, vol. 24(3), pages 5-25, December.
  46. Frank Lichtenberg, 2006. "Has Using Newer Drugs Reduced Admissions to Hospitals and Nursing Homes?," Swiss Journal of Economics and Statistics (SJES), Swiss Society of Economics and Statistics (SSES), vol. 142(V), pages 69-75.
  47. Adriana Lleras-Muney & Frank R. Lichtenberg, 2005. "Are the More Educated More Likely to Use New Drugs?," Annals of Economics and Statistics, GENES, issue 79-80, pages 671-696.
  48. Frank Lichtenberg, 2005. "The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001," International Journal of Health Economics and Management, Springer, vol. 5(1), pages 47-73, January.
  49. Lichtenberg, Frank R., 2004. "Sources of U.S. longevity increase, 1960-2001," The Quarterly Review of Economics and Finance, Elsevier, vol. 44(3), pages 369-389, July.
  50. Lichtenberg, Frank R., 2003. "The effect of new drug approvals on HIV mortality in the US, 1987-1998," Economics & Human Biology, Elsevier, vol. 1(2), pages 259-266, June.
  51. Frank R. Lichtenberg, 2003. "The benefits to society of new drugs: a survey of the econometric evidence," Proceedings, Federal Reserve Bank of Dallas, issue Sep, pages 43-59.
  52. Frank R. Lichtenberg & Tomas J. Philipson, 2002. "The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry," Journal of Law and Economics, University of Chicago Press, vol. 45(S2), pages 643-672.
  53. Lichtenberg Frank R., 2002. "The Effects of Medicare on Health Care Utilization and Outcomes," Forum for Health Economics & Policy, De Gruyter, vol. 5(1), pages 1-29, January.
  54. Bruno Van Pottelsberghe De La Potterie & Frank Lichtenberg, 2001. "Does Foreign Direct Investment Transfer Technology Across Borders?," The Review of Economics and Statistics, MIT Press, vol. 83(3), pages 490-497, August.
  55. Bill Lehr & Frank Lichtenberg, 1999. "Information technology and its impact on firm-level productivity: evidence from government and private data sources, 1977-1993," Canadian Journal of Economics, Canadian Economics Association, vol. 32(2), pages 335-362, April.
  56. Palia, Darius & Lichtenberg, Frank, 1999. "Managerial ownership and firm performance: A re-examination using productivity measurement," Journal of Corporate Finance, Elsevier, vol. 5(4), pages 323-339, December.
  57. William Lehr & Frank R. Lichtenberg, 1998. "Computer Use and Productivity Growth in US Federal Government Agencies, 1987–92," Journal of Industrial Economics, Wiley Blackwell, vol. 46(2), pages 257-279, June.
  58. Lichtenberg, Frank R. & Pottelsberghe de la Potterie, Bruno v., 1998. "International R&D spillovers: A comment," European Economic Review, Elsevier, vol. 42(8), pages 1483-1491, September.
  59. Maryann P. Feldman & Frank R. Lichtenberg, 1998. "The Impact and Organization of Publicly-Funded Research and development in the European Community," Annals of Economics and Statistics, GENES, issue 49-50, pages 199-222.
  60. Lichtenberg, Frank R, 1996. "Do (More and Better) Drugs Keep People Out of Hospitals?," American Economic Review, American Economic Association, vol. 86(2), pages 384-388, May.
  61. J. Strand & M. Marchand & Y. Chung & R. Färe & F. Lichtenberg & W. Rogerson & J. Weidmann & P. Kort & P. Schönfeld, 1996. "Book Reviews," Journal of Economics, Springer, vol. 63(3), pages 325-345, October.
  62. Lichtenberg, Frank R., 1995. "Rejoinder to comment by Maarten Vendrik," Journal of Economic Behavior & Organization, Elsevier, vol. 28(3), pages 455-456, December.
  63. Lichtenberg, Frank R., 1995. "Labour market institutions, liquidity constraints, and macroeconomic stability," Journal of Economic Behavior & Organization, Elsevier, vol. 28(1), pages 145-154, September.
  64. Lichtenberg, Frank R. & Pushner, George M., 1994. "Ownership structure and corporate performance in Japan," Japan and the World Economy, Elsevier, vol. 6(3), pages 239-261, October.
  65. Lichtenberg, Frank R, 1994. "Testing the Convergence Hypothesis," The Review of Economics and Statistics, MIT Press, vol. 76(3), pages 576-579, August.
  66. Lichtenberg, Frank R., 1992. "Industrial de-diversification and its consequences for productivity," Journal of Economic Behavior & Organization, Elsevier, vol. 18(3), pages 427-438, August.
  67. Lichtenberg, Frank R, 1991. "The Managerial Response to Regulation of Financial Reporting for Segments of a Business Enterprise," Journal of Regulatory Economics, Springer, vol. 3(3), pages 241-249, September.
  68. Lichtenberg, Frank R & Siegel, Donald, 1991. "The Impact of R&D Investment on Productivity--New Evidence Using Linked R&D-LRD Data," Economic Inquiry, Western Economic Association International, vol. 29(2), pages 203-229, April.
  69. Lichtenberg, Frank R., 1990. "Issues in measuring industrial R&D," Research Policy, Elsevier, vol. 19(2), pages 157-163, April.
  70. Lichtenberg, Frank R & Siegel, Donald, 1990. "The Effect of Ownership Changes on the Employment and Wages of Central Office and Other Personnel," Journal of Law and Economics, University of Chicago Press, vol. 33(2), pages 383-408, October.
  71. Lichtenberg, Frank R. & Siegel, Donald, 1990. "The effects of leveraged buyouts on productivity and related aspects of firm behavior," Journal of Financial Economics, Elsevier, vol. 27(1), pages 165-194, September.
  72. Lichtenberg, Frank R., 1989. "How elastic is the government's demand for weapons?," Journal of Public Economics, Elsevier, vol. 40(1), pages 57-78, October.
  73. Lichtenberg, Frank R & Griliches, Zvi, 1989. "Errors of Measurement in Output Deflators," Journal of Business & Economic Statistics, American Statistical Association, vol. 7(1), pages 1-9, January.
  74. Frank R. Lichtenberg & Donald Siegel, 1989. "The Effect Of Control Changes On The Productivity Of U.S. Manufacturing Plants," Journal of Applied Corporate Finance, Morgan Stanley, vol. 2(2), pages 60-67, June.
  75. Lichtenberg, Frank R, 1989. "Contributions to Federal Election Campaigns by Government Contractors," Journal of Industrial Economics, Wiley Blackwell, vol. 38(1), pages 31-48, September.
  76. Lichtenberg, Frank R., 1989. "IR & D project data and theories of R & D investment," Journal of Economic Dynamics and Control, Elsevier, vol. 13(2), pages 271-282, April.
  77. Lichtenberg, Frank R., 1988. "The burden of government : , Stanford: Hoover Institution Press, 1986. x + 188 pp., $23.95," Journal of Comparative Economics, Elsevier, vol. 12(2), pages 304-305, June.
  78. Lichtenberg, Frank R, 1988. "Estimation of the Internal Adjustment Costs Model Using Longitudinal Establishment Data," The Review of Economics and Statistics, MIT Press, vol. 70(3), pages 421-430, August.
  79. Lichtenberg, Frank R, 1988. "The Private R&D Investment Response to Federal Design and Technical Competitions," American Economic Review, American Economic Association, vol. 78(3), pages 550-559, June.
  80. Frank R. Lichtenberg & Donald Siegel, 1987. "Productivity and Changes in Ownership of Manufactoring Plants," Brookings Papers on Economic Activity, Economic Studies Program, The Brookings Institution, vol. 18(3, Specia), pages 643-684.
  81. Bartel, Ann P & Lichtenberg, Frank R, 1987. "The Comparative Advantage of Educated Workers in Implementing New Technology," The Review of Economics and Statistics, MIT Press, vol. 69(1), pages 1-11, February.
  82. Lichtenberg, Frank R., 1987. "Changing market opportunities and the structure of R & D investment : The case of energy," Energy Economics, Elsevier, vol. 9(3), pages 154-158, July.
  83. Lichtenberg, Frank R, 1987. "The Effect of Government Funding on Private Industrial Research and Development: A Re-assessment," Journal of Industrial Economics, Wiley Blackwell, vol. 36(1), pages 97-104, September.
  84. Lichtenberg, Frank R., 1986. "Energy prices and induced innovation," Research Policy, Elsevier, vol. 15(2), pages 67-75, April.
  85. Griliches, Zvi & Lichtenberg, Frank, 1984. "Interindustry Technology Flows and Productivity Growth: A Re-examination," The Review of Economics and Statistics, MIT Press, vol. 66(2), pages 324-329, May.
  86. Lichtenberg, Frank R, 1984. "The Relationship between Federal Contract R&D and Company R&D," American Economic Review, American Economic Association, vol. 74(2), pages 73-78, May.

Chapters

  1. Frank R. Lichtenberg, 2022. "The impact of biomedical innovation on longevity and health," Chapters, in: Cristiano Antonelli (ed.), Elgar Encyclopedia on the Economics of Knowledge and Innovation, chapter 23, pages 186-198, Edward Elgar Publishing.
  2. Rebecca A. Pulk & Jove Graham & Frank R. Lichtenberg & Daniel Maeng & Marc S. Williams & Eric Wright, 2018. "The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 273-304, National Bureau of Economic Research, Inc.
  3. Frank R. Lichtenberg, 2016. "The Impact of Biomedical Research on U.S. Cancer Mortality: A Bibliometric Analysis," NBER Chapters, in: Measuring and Modeling Health Care Costs, pages 475-504, National Bureau of Economic Research, Inc.
  4. Frank R. Lichtenberg, 2012. "The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans: Evidence from the 2004 National Nursing Home Survey," Advances in Health Economics and Health Services Research, in: The Economics of Medical Technology, pages 73-101, Emerald Group Publishing Limited.
  5. Adriana Lleras-Muney & Frank R. Lichtenberg, 2010. "Are the More Educated More Likely to Use New Drugs?," NBER Chapters, in: Contributions in Memory of Zvi Griliches, pages 671-696, National Bureau of Economic Research, Inc.
  6. Frank R. Lichtenberg, 2010. "The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program," Advances in Health Economics and Health Services Research, in: Pharmaceutical Markets and Insurance Worldwide, pages 273-292, Emerald Group Publishing Limited.
  7. Frank R. Lichtenberg & Gautier Duflos, 2008. "Pharmaceutical innovation and the longevity of Australians: A first look," Advances in Health Economics and Health Services Research, in: Beyond Health Insurance: Public Policy to Improve Health, pages 95-117, Emerald Group Publishing Limited.
  8. Frank R. Lichtenberg, 2007. "Pharmaceutical Innovation and US Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data," NBER Chapters, in: Frontiers in Health Policy Research, Volume 10, National Bureau of Economic Research, Inc.
  9. Frank R. Lichtenberg, 2005. "Pharmaceutical Knowledge-Capital Accumulation and Longevity," NBER Chapters, in: Measuring Capital in the New Economy, pages 237-274, National Bureau of Economic Research, Inc.
  10. Frank R. Lichtenberg, 2002. "The Effects of Medicare on Health Care Utilization and Outcomes," NBER Chapters, in: Frontiers in Health Policy Research, Volume 5, pages 27-52, National Bureau of Economic Research, Inc.
  11. Frank R. Lichtenberg, 2001. "The Allocation of Publicly Funded Biomedical Research," NBER Chapters, in: Medical Care Output and Productivity, National Bureau of Economic Research, Inc.
  12. Lichtenberg, Frank R., 1995. "Economics of defense R&D," Handbook of Defense Economics, in: Keith Hartley & Todd Sandler (ed.), Handbook of Defense Economics, edition 1, volume 1, chapter 15, pages 431-457, Elsevier.
  13. Zvi Griliches & Frank R. Lichtenberg, 1984. "R&D and Productivity Growth at the Industry Level: Is There Still a Relationship?," NBER Chapters, in: R&D, Patents, and Productivity, pages 465-502, National Bureau of Economic Research, Inc.

    RePEc:eme:ahes11:s0731-2199(08)19005-7 is not listed on IDEAS
    RePEc:eme:ahes11:s0731-2199(2010)0000022015 is not listed on IDEAS
    RePEc:eme:ahes11:s0731-2199(2012)0000023006 is not listed on IDEAS

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Rankings

This author is among the top 5% authors according to these criteria:
  1. Average Rank Score
  2. Number of Works
  3. Number of Distinct Works
  4. Number of Distinct Works, Weighted by Simple Impact Factor
  5. Number of Distinct Works, Weighted by Recursive Impact Factor
  6. Number of Distinct Works, Weighted by Number of Authors
  7. Number of Distinct Works, Weighted by Number of Authors and Simple Impact Factors
  8. Number of Distinct Works, Weighted by Number of Authors and Recursive Impact Factors
  9. Number of Citations
  10. Number of Citations, Discounted by Citation Age
  11. Number of Citations, Weighted by Simple Impact Factor
  12. Number of Citations, Weighted by Simple Impact Factor, Discounted by Citation Age
  13. Number of Citations, Weighted by Recursive Impact Factor
  14. Number of Citations, Weighted by Recursive Impact Factor, Discounted by Citation Age
  15. Number of Citations, Weighted by Number of Authors
  16. Number of Citations, Weighted by Number of Authors, Discounted by Citation Age
  17. Number of Citations, Weighted by Number of Authors and Simple Impact Factors
  18. Number of Citations, Weighted by Number of Authors and Simple Impact Factors, Discounted by Citation Age
  19. Number of Citations, Weighted by Number of Authors and Recursive Impact Factors
  20. Number of Citations, Weighted by Number of Authors and Recursive Impact Factors, Discounted by Citation Age
  21. h-index
  22. Number of Registered Citing Authors
  23. Number of Registered Citing Authors, Weighted by Rank (Max. 1 per Author)
  24. Number of Journal Pages
  25. Number of Journal Pages, Weighted by Simple Impact Factor
  26. Number of Journal Pages, Weighted by Recursive Impact Factor
  27. Number of Journal Pages, Weighted by Number of Authors
  28. Number of Journal Pages, Weighted by Number of Authors and Simple Impact Factors
  29. Number of Journal Pages, Weighted by Number of Authors and Recursive Impact Factors
  30. Number of Abstract Views in RePEc Services over the past 12 months
  31. Number of Abstract Views in RePEc Services over the past 12 months, Weighted by Number of Authors
  32. Number of Downloads through RePEc Services over the past 12 months, Weighted by Number of Authors
  33. Euclidian citation score
  34. Breadth of citations across fields
  35. Wu-Index
  36. Record of graduates

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 34 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (30) 2001-12-26 2002-02-10 2002-09-11 2002-11-28 2003-06-16 2003-06-16 2003-11-16 2004-02-29 2004-08-02 2004-11-22 2006-04-08 2006-08-26 2008-05-17 2008-05-17 2009-02-22 2009-06-17 2010-04-17 2010-11-20 2011-09-16 2012-01-25 2012-07-29 2012-12-06 2015-06-13 2015-12-28 2017-04-02 2018-05-21 2018-12-24 2019-02-04 2019-04-15 2022-10-10. Author is listed
  2. NEP-INO: Innovation (8) 2006-04-08 2006-10-14 2010-04-17 2012-01-25 2012-07-29 2012-12-06 2015-06-13 2019-04-15. Author is listed
  3. NEP-AGE: Economics of Ageing (2) 2008-05-17 2012-12-06
  4. NEP-IAS: Insurance Economics (2) 2009-06-17 2015-12-28
  5. NEP-TID: Technology and Industrial Dynamics (2) 2003-11-16 2019-04-15
  6. NEP-COM: Industrial Competition (1) 2003-11-16
  7. NEP-DEM: Demographic Economics (1) 2012-12-06
  8. NEP-DEV: Development (1) 2002-02-10
  9. NEP-EDU: Education (1) 2003-06-16
  10. NEP-HAP: Economics of Happiness (1) 2009-06-17
  11. NEP-LAB: Labour Economics (1) 2002-09-21
  12. NEP-LMA: Labor Markets - Supply, Demand, and Wages (1) 2015-06-13
  13. NEP-MIC: Microeconomics (1) 2002-06-26
  14. NEP-PUB: Public Finance (1) 1998-07-06

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Frank Lichtenberg should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.